IDEAYA Biosciences Cash Flow Statement
NASDAQ: IDYAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.11+0.05 (+0.14%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEAYA Biosciences free cash flow
In fiscal 2025, IDEAYA Biosciences generated -$71.1 million of operating cash flow and spent $2.4 million on capital expenditures. That left free cash flow of -$73.5 million, a free-cash-flow margin of -33.6% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
IDEAYA Biosciences cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -113.70M | -274.48M | -112.96M | -58.66M | -49.76M | -34.49M | -41.98M | -34.35M | -11.86M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 2.70M | 2.39M | 2.48M | 2.10M | 1.73M | 1.38M | 1.25M | 886.00K | 391.00K |
| Stock-Based Compensation | 46.12M | 34.75M | 18.49M | 11.63M | 8.24M | 3.61M | 2.17M | 950.00K | 136.00K |
| Change in Working Capital | -5.14M | 2.12M | -12.97M | -45.84M | -21.79M | 81.61M | -2.16M | 79.00K | 585.00K |
| Operating Cash Flow | -71.10M | -247.58M | -115.22M | -87.17M | -55.78M | 55.46M | -39.31M | -27.62M | -12.22M |
| Capital Expenditures | -2.37M | -3.86M | -2.37M | -3.44M | -2.64M | -493.00K | -1.35M | -1.71M | -1.76M |
| Investing Cash Flow | 69.98M | -502.56M | -158.46M | -33.40M | -69.67M | -146.24M | 2.27M | -63.18M | -8.93M |
| Financing Cash Flow | 29.78M | 677.55M | 362.72M | 97.17M | 145.45M | 128.75M | 50.61M | 105.38M | 17.49M |
| Net Change in Cash | 28.66M | -72.59M | 89.04M | -23.41M | 20.01M | 37.97M | 13.56M | 14.58M | -3.66M |
| Free Cash Flow | -73.47M | -251.44M | -117.59M | -90.62M | -58.42M | 54.97M | -40.67M | -29.33M | -13.98M |
This table shows 9 annual periods of IDEAYA Biosciences's cash flow statement, from FY 2025 back to FY 2017, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow IDYA's reporting calendar. What is a cash flow statement?